

Addressing
Antibiotic
Resistance

BARDEX[®] I.C.[™] Anti-Infective
Foley Catheters

with Bacti-Guard^{®} Silver Alloy Coating and Bard[®] Hydrogel*

**New insights into
addressing antibiotic
resistance**

Reducing antibiotic use by
avoiding catheter-associated
urinary tract infections
(CAUTIs)

Reduce antibiotic use by avoiding catheter-associated urinary tract infections (CAUTIs)

Antibiotic Resistance: The CAUTI Connection

The unnecessary use and misuse of antibiotics has led to a significant healthcare problem – antibiotic resistance.

- More than 70% of the bacteria that cause nosocomial (hospital-acquired) infections are resistant to at least one of the drugs most commonly used to treat them¹
- Patients infected with drug-resistant organisms are more likely to have longer hospital stays and require more treatment with second- or third-choice drugs that may be less effective, more toxic, and/or more expensive¹


Catheter-associated urinary tract infections (CAUTIs) contribute to the problem of antibiotic resistance:

- CAUTIs comprise the largest institutional reservoir of antibiotic-resistant pathogens²
- Patients presenting with asymptomatic bacteriuria are nevertheless treated with antibiotics 71% of the time and intravenous antibiotics 28% of the time³
- Patients presenting with symptomatic CAUTI are treated with intravenous antibiotics 49% of the time³

Reducing CAUTIs by 26% to 47%^{2,5,6} with the Bardex® I.C. Anti-Infective Foley Catheter with Bacti-Guard® silver alloy coating and Bard® Hydrogel can mean reducing antibiotic use**

Urinary Tract Infections (UTIs) Comprise a Significant Percentage of All Nosocomial Infections

Nosocomial UTIs account for over 40% of all hospital-acquired infections⁴



The use of anti-infective urinary catheters is recommended for addressing the public health threat of antibiotic resistance.


Addressing Antibiotic Resistance with Proven Technology

The Bardex® I.C. Anti-Infective Foley Catheter uses Bacti-Guard®* silver alloy coating technology, which is clinically proven to reduce catheter-associated urinary tract infections.^{2,5,6}

Standardizing on the Bardex® I.C. Anti-Infective Foley Catheter with Bacti-Guard®* silver alloy coating and Bard® Hydrogel reduces antibiotic use

By adopting infection control technologies, such as the Bardex® I.C. Anti-Infective Foley Catheter with Bacti-Guard®* silver alloy coating, antibiotic use may be significantly minimized.

- Antibiotic usage, targeted at UTIs, is reduced by over 40% (RR less than 0.6)^{3,7}
- IV antibiotic usage, targeted at UTIs, is reduced by over 50% (RR less than 0.5)³



Recommended by a federal task force – CDC, FDA, and NIH – to reduce antibiotic-resistant pathogens:⁹

Address Antibiotic Resistance by Avoiding Infection

- Hospital-acquired urinary tract infections (UTIs) account for over 40% of all hospital-acquired infections.⁴
- Catheter-associated UTIs (CAUTIs) comprise the largest institutional reservoir of antibiotic-resistant pathogens.²
- Use of the Bardex[®] I.C. Anti-Infective Foley Catheter with Bacti-Guard^{®*} silver alloy coating and Bard[®] Hydrogel is clinically proven to decrease the incidence of CAUTIs by 26% to 47%.^{2,5,6}
- Reduce antibiotic usage and address antibiotic resistance by standardizing on the Bardex[®] I.C. Anti-Infective Foley Catheter with Bacti-Guard^{®*} silver alloy coating and Bard[®] Hydrogel.^{3,7,8,9}
- Use of the Bardex[®] I.C. Anti-Infective Foley Catheter with Bacti-Guard^{®*} silver alloy coating and Bard[®] Hydrogel does not select for CAUTIs caused by silver-resistant organisms.²

References

1. Wong ES. Guideline for prevention of catheter-associated urinary tract infections. Accessed August 29, 2003.
2. Maki DG, Tambyah PA. Engineering out the risk of infection with urinary catheters. *Emerg Infect Dis.* 2001;7:342-347.
3. Thomas L, Valainis G, Johnson J. A multi-site, cohort-matched trial of an anti-infective urinary catheter [abstract]. Presented at Society for Healthcare Epidemiology of America (SHEA), 2002.
4. Salgado CD, Karchmer TB, Farr BM. Prevention of catheter-associated urinary tract infections. In: Wenzel RP, ed. *Prevention and Control of Nosocomial Infections*. 4th ed. Philadelphia: Lippincott Williams & Wilkins. 2003;297-311.
5. Karchmer TB, Giannetta ET, Muto CA, Strain BA, Farr BM. A randomized crossover study of silver-coated urinary catheters in hospitalized patients. *Arch Int Med.* 2000;160:3294-3298.
6. Saint S, Veenstra DL, Sullivan SD, Chenoweth C, Fendrick AM. The potential clinical and economic benefits of silver alloy urinary catheters in preventing urinary tract infection. *Arch Int Med.* 2000;160:2670-2675.
7. Hazamy P. Evaluation of a Silver/Hydrogel-coated Urinary Catheter for Prevention of Catheter-associated Urinary Tract Infection in a Cancer Institute [abstract]. Presented at Association for Professionals in Infection Control and Epidemiology (APIC), 2003.
8. Newton T, Still JM, Law E. A comparison of the effect of early insertion of standard latex and silver-impregnated latex Foley catheters on urinary tract infections in burn patients. *Infect Control Hosp Epidemiol.* 2002;23:217-218.
9. A Public Health Action Plan to Combat Antimicrobial Resistance. Published by the CDC, FDA, NIH, et al. January 2001.

www.bardmedical.com

Bard Medical Division
C.R. Bard, Inc.
8195 Industrial Blvd.
Covington, GA 30014
800-526-4455



Please consult product label and insert for any indications, contraindications, hazards, warnings, cautions, and directions for use.

*The Foley catheters in the Bardex[®] I.C. System contain Bacti-Guard[®] silver alloy coating, licensed from Adhesive Technology (International) Licensing, B.V.

Bard and Bardex are registered trademarks and the I.C. logo is a trademark of C.R. Bard, Inc. or an affiliate.

Bacti-Guard is a registered trademark of Adhesive Technology (International) Licensing, B.V.

©2004 C.R. Bard, Inc. All Rights Reserved. 0405-15 R06/04 THP P06/04 5M